DRUG
Bright Minds BiosciencesDRUG
DRUG
About: Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
76,659% more capital invested
Capital invested by funds: $230K [Q3] → $176M (+$176M) [Q4]
2,400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 1
400% more funds holding
Funds holding: 6 [Q3] → 30 (+24) [Q4]
76.25% more ownership
Funds ownership: 4.29% [Q3] → 80.54% (+76.25%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$85
141%
upside
Avg. target
$89
152%
upside
High target
$93
163%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 20% 1-year accuracy 10 / 51 met price target | 141%upside $85 | Buy Reiterated | 19 Feb 2025 |
Piper Sandler Yasmeen Rahimi 42% 1-year accuracy 10 / 24 met price target | 163%upside $93 | Overweight Initiated | 23 Jan 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 months ago
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety.
Neutral
GlobeNewsWire
2 months ago
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an advisory capacity.
Neutral
The Motley Fool
4 months ago
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
Neutral
GlobeNewsWire
4 months ago
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
Positive
Seeking Alpha
5 months ago
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform targets serotonin regulation, aiming to create selective therapies with fewer side effects. DRUG's recent $35 million private placement funds Phase 2 trials, enhancing its financial outlook and potential for significant revenue if BMB-101 is successful.
Neutral
Business Wire
5 months ago
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial.
Neutral
GlobeNewsWire
5 months ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Positive
Finbold
5 months ago
Monster insider trading alert for this penny stock that rallied $3,700% in a week
This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed to historic levels, and it seems several investors have profited significantly from this momentum.
Neutral
GlobeNewsWire
5 months ago
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Neutral
GlobeNewsWire
5 months ago
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program. Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls.
Charts implemented using Lightweight Charts™